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ABSTRACT
Objective: To analyse associations between the clinical
status of patients with rheumatoid arthritis (RA) and the
gross domestic product (GDP) of their resident country.
Methods: The Quantitative Standard Monitoring of
Patients with Rheumatoid Arthritis (QUEST–RA) cohort
includes clinical and questionnaire data from 6004
patients who were seen in usual care at 70 rheumatology
clinics in 25 countries as of April 2008, including 18
European countries. Demographic variables, clinical
characteristics, RA disease activity measures, including
the disease activity score in 28 joints (DAS28), and
treatment-related variables were analysed according to
GDP per capita, including 14 ‘‘high GDP’’ countries with
GDP per capita greater than US$24 000 and 11 ‘‘low
GDP’’ countries with GDP per capita less than US$11 000.
Results: Disease activity DAS28 ranged between 3.1 and
6.0 among the 25 countries and was significantly
associated with GDP (r = 20.78, 95% CI 20.56 to
20.90, r
2 = 61%). Disease activity levels differed
substantially between ‘‘high GDP’’ and ‘‘low GDP’’
countries at much greater levels than according to
whether patients were currently taking or not taking
methotrexate, prednisone and/or biological agents.
Conclusions: The clinical status of patients with RA was
correlated significantly with GDP among 25 mostly
European countries according to all disease measures,
associated only modestly with the current use of
antirheumatic medications. The burden of arthritis
appears substantially greater in ‘‘low GDP’’ than in ‘‘high
GDP’’ countries. These findings may alert healthcare
professionals and designers of health policy towards
improving the clinical status of patients with RA in all
countries.
Health disparities, including high mortality rates,
are associated with low socioeconomic status in
many specific diseases in many countries.
1–6
Furthermore, differences in gross domestic product
(GDP) in different countries are associated signifi-
cantly with differences in mortality rates among
countries.
7–9 Most reports of these observations are
based on surveys and national databases, with
relatively limited information from clinical settings
based on physical examination, laboratory tests,
medications and patient self-report information
concerning functional status, pain, psychosocial
distress, etc, to understand further the basis for
these disparities. Furthermore, little is known
concerning associations of GDP and clinical out-
comes of chronic disabling musculoskeletal condi-
tions such as rheumatoid arthritis (RA).
A multinational database Quantitative Standard
Monitoring of Patients with Rheumatoid Arthritis
(QUEST–RA)
10 11 was established to assess 100
unselected consecutive patients with RA per clinic
and included 25 countries by April 2008.
Considerable variation was observed in clinical
status in different countries according to most
clinical measures, whether derived from the phy-
sician, patient or laboratory, as well as the
composite RA disease activity score in 28 joints
(DAS28) index.
12 In this report, we compare
demographic characteristics, RA disease activity
measures and treatment-related variables between
‘‘high GDP’’ and ‘‘low GDP’’ countries, and analyse
associations between DAS28 and GDP.
PATIENTS AND METHODS
Establishment of database
QUEST–RA was established in 2005 with the
objectives of promoting quantitative assessment in
usual rheumatology care, and to develop a baseline
cross-sectional database of consecutive RA patients
seen outside of clinical trials in regular care in
many countries. Three or more rheumatologists
were asked to enroll 100 consecutive unselected
patients in each country.
10 As of April 2008, the
programme enrolled 6004 patients from 71 sites in
25 countries, including Argentina, Brazil, Canada,
Denmark, Estonia, Finland, France, Germany,
Greece, Hungary, Ireland, Italy, Kosovo, Latvia,
Lithuania, The Netherlands, Poland, Russia, Serbia,
Spain, Sweden, Turkey, United Arab Emirates, the
UK and the USA.
11
The study was carried out in compliance with
the Helsinki Declaration. Ethics Committees or
Internal Review Boards of participating institutes
approved the study, and a written informed
consent was obtained from the patients.
Physician assessment measures
All patients were assessed according to a standard
protocol to evaluate RA.
13 The physician review
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1666 Ann Rheum Dis 2009;68:1666–1672. doi:10.1136/ard.2009.109983included a formal examination to count the number of swollen
and tender joints, report of radiographic erosions, erythrocyte
sedimentation rate (ESR) and rheumatoid factor (RF) positivity
according to local reference values. Physicians reported the use
of disease-modifying antirheumatic drugs (DMARD), including:
(1) the interval between the first symptoms and the start of the
first DMARD; (2) the number of DMARD ever used; (3) the use
of methotrexate, oral glucocorticoids, biological agents and
other DMARD and (4) the start and stop dates for each
DMARD used. The total duration of DMARD therapy as a
percentage of disease duration was computed.
Patient self-report questionnaire measures
Patients completed a 4-page self-report questionnaire, which
included demographic data, physical function, pain, global
estimate and psychological distress. Demographic data included
date of birth, gender, years of formal education, race and
smoking status, as well as weight and height, to calculate body
mass index (BMI). A standard health assessment questionnaire
(HAQ)
14 assesses physical function in activities of daily living
with four response categories: 0, without any difficulty; 1, with
some difficulty; 2, with much difficulty; 3, unable to do. Visual
analogue scales (0 = best to 10 = worst) were completed for
pain and patient estimate of his/her global health (GH).
Psychological distress was assessed as the capacity to cope with
stress, anxiety and depression, queried and calculated in the
HAQ format for psychological HAQ scored 0–3.
15
Disease activity score
The DAS28
12 is the most widely used overall measure for RA
disease activity, comprising two physical examination mea-
sures, a swollen 28-joint count (SJC28) and a tender 28-joint
count (TJC28); one laboratory measure, ESR; and one patient
self-report measure, a global estimate of health status (GH).
DAS28 ranges from 0 to 9.1 (low–high), calculated from the
Table 1 Comparison of patient characteristics, RA disease activity measures and treatment-related variables
in the QUEST–RA study in ‘‘high GDP’’ and ‘‘low GDP’’ countries
Total
‘‘High GDP’’
countries
‘‘Low GDP’’
countries p Value*
N 6004 3719 2285
Patient characteristics
Female, % 79% 75% 86% ,0.001
Age, years, mean 56 58 54 ,0.001
Education, years, median 11 11 11 0.16
Smoking now, % 17% 19% 14% ,0.001
BMI, mean 26 26 26 0.63
Disease duration, years, mean 11 11 11 0.038
Disease activity measures
DAS28 (0–9.1), mean 4.2 3.7 5.1 ,0.001
Physician
SJC (0–28), median 2 1 4 ,0.001
TJC (0–28), median 4 2 8 ,0.001
Physician global (0–10), median 2.4 1.7 3.7 ,0.001
Patient self-report
HAQ physical function (0–3) median 0.88 0.75 1.3 ,0.001
Pain VAS (0–10), median 4.1 3.3 4.9 ,0.001
Patient global VAS (0–10), median 4.2 3.2 4.9 ,0.001
Psychological HAQ (0–3), mean 0.82 0.7 1.3 ,0.001
Laboratory/imaging
ESR, median 22 18 30 ,0.001
RF-positive, % 74% 72% 76% 0.001
Erosive disease, % 63% 58% 72% ,0.001
In patients with disease duration (2 years 23% 40% ,0.001
In patients with disease duration >10 years 79% 84% 0.001
Treatment-related variables
Patients taking DMARD ever, % 97% 97% 97% 0.75
Delay to start a DMARD, months, median 9 9 9 0.063
No of DMARD ever taken, mean 2.7 2.8 2.5 ,0.001
Methotrexate ever, % of patients 85% 86% 84% ,0.001
Methotrexate now, % of patients 63% 63% 62% 0.36
Prednisone ever, % of patients 71% 66% 80% ,0.001
Prednisone now, % of patients 49% 42% 60% ,0.001
Biologicals ever, % of patients 23% 31% 9.4% ,0.001
Biologicals now, % of patients 18% 25% 7.5% ,0.001
Any DMARD, % of disease duration 72% 75% 67% 0.085
Methotrexate, % of disease duration 31% 32% 30% 0.18
Biologicals, % of disease duration 3.9% 5.6% 1.8% 0.001
*Unadjusted p values are presented.
BMI, body mass index; DAS28, disease activity score in 28 joints; DMARD, disease-modifying antirheumatic drug; ESR,
erythrocyte sedimentation rate; GDP, gross domestic product; HAQ, health assessment questionnaire; RA, rheumatoid arthritis; RF,
rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale.
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0.014*(GH).
Gross domestic product
The GDP of each country in 2005 was obtained from a database
of the International Monetary Fund
16 and is expressed as
UD$1000 or Euros (J) per capita (with an exchange rate of
US$1.25 = J1.0 in 2005). GDP ranged from 3.5 to 49,
including 14 ‘‘high GDP’’ countries with GDP per capita greater
than US$24 000 and 11 ‘‘low GDP’’ countries with GDP per
capita less than US$11 000.
Statistical methods
Descriptive results for each country are presented as mean,
median and percentages. Comparisons of demographic vari-
ables, clinical characteristics, RA disease activity measures and
treatment-related variables within and/or between ‘‘high GDP’’
and ‘‘low GDP’’ countries were performed using parametric and
non-parametric tests for continuous variables and the x
2 test for
categorical variables. Linear regression models were applied to
analyse possible associations between DAS28 and GDP.
RESULTS
Patients
The 6004 patients in the QUEST–RA database, from 71 clinics
in 25 countries, represent a typical RA cohort in demographic
features, with a mean age of 56 years, 79% women, and a mean
disease duration of 11 years (table 1). Patients were younger and
more likely to be women in ‘‘low GDP’’ compared with ‘‘high
GDP’’ countries, whereas years of formal education, BMI and
disease duration were similar (table 1). Patient characteristics
are presented for each European and non-European country, in
descending order of GDP in table 2.
Disease activity
Patients in ‘‘low GDP’’ countries had statistically significantly
higher disease activity levels in all individual disease activity
measures, including physician-derived measures, patient self-
report scores and laboratory measures, as well as the composite
index DAS28 (table 1). The percentage of patients with positive
RF varied between 61% and 90% between countries (table 3),
although the overall difference was only 4% between ‘‘high
GDP’’ and ‘‘low GDP’’ countries (table 1). Erosive disease was
less prevalent in ‘‘high GDP’’ countries, with differences of 14%,
although with differences of only 5% in patients with more
than 10 years of disease (table 1).
Drug therapies
DMARD were taken by 88–100% of all patients in the 25
countries (table 4), with no differences between ‘‘high GDP’’
and ‘‘low GDP’’ countries (table 1); the mean number of
DMARD was 2.7. The median delay between first symptoms
and initiation of the first DMARD ranged from less than
6 months in three countries to one year or more in 10 countries
(table 4), with no significant difference between ‘‘high GDP’’
and ‘‘low GDP’’ countries (table 1). Methotrexate was taken by
69–98%, prednisone by 30–97% and biological agents by 1–54%
of patients. DMARD were taken for less than 50% of disease
duration in the UK, Ireland, Hungary, Latvia, Lithuania and
Argentina, and for more than 100% in Finland, Greece and
Table 2 Patient characteristics in the QUEST–RA study in Europe and other countries, in descending order of GDP
Country
GDP 2005 per
capita
(US$1000) Sites Patients Women, %
Age, years,
mean
Education,
years,
median
Smoking
now, % BMI, mean
Disease
duration,
years, mean
Europe
Ireland 48.7 3 240 64 56 12 24 25 11
Denmark 47.9 3 301 77 58 10 31 25 12
Sweden 39.6 3 260 72 59 10 19 25 12
The Netherlands 38.9 3 317 66 59 11 22 26 9
Finland 37.3 3 304 72 59 9 15 27 14
UK 37.3 3 145 78 60 12 19 25 15
France 35.0 4 389 78 55 10 19 25 13
Germany 33.9 2 225 84 59 10 13 26 13
Italy 30.5 4 336 78 61 8 16 25 10
Spain 26.1 3 302 74 60 10 17 26 11
Greece 25.6 3 300 76 58 12 15 26 12
Hungary 10.9 3 153 87 58 12 24 25 13
Estonia 10.3 3 168 85 56 12 14 26 12
Poland 8.0 7 642 87 53 12 11 25 12
Lithuania 7.5 2 300 83 54 13 7 26 11
Latvia 7.0 1 79 80 53 13 18 27 13
Serbia 3.5 1 100 88 59 8 18 26 10
Kosovo 3.5 1 100 84 55 8 5 28 8
Non-Europe
USA 41.9 3 301 73 57 13 20 28 9
Canada 35.2 1 100 79 58 12 30 27 12
UAE 32.4 2 199 86 45 15 6 26 6
Russia 5.3 3 73 85 54 13 15 26 6
Turkey 5.0 3 309 86 52 5 13 27 12
Brazil 4.8 5 115 89 52 8 13 25 8
Argentina 4.7 2 246 90 51 9 21 26 10
Total 71 6004 79 56 11 17 26 11
BMI, body mass index; GDP, gross domestic product; UAE, United Arab Emirates.
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use of two or more DMARD. Methotrexate covered 21–57% of
disease duration and the use of biologic agents covered 0.2–14%
(table 4).
Differences in the DAS28 scores of patients who were taking
or not taking methotrexate were small within ‘‘high GDP’’
countries (3.6 vs 3.8) and ‘‘low GDP’’ countries (5.1 vs 5.2) but
large between ‘‘high GDP’’ versus ‘‘low GDP’’ countries
(p,0.001; table 5). Similar patterns were seen for patients
who were currently taking or not taking prednisone. Patients
who were taking or not taking biological agents in ‘‘high GDP’’
countries had similar disease activity levels of 3.7, whereas in
‘‘low GDP’’ countries those who were taking biological agents
had a statistically significantly lower mean DAS28 of 4.4
compared with patients who were not taking biological agents
(DAS28 5.2; p,0.001).
Linear regression models for GDP and disease activity
The mean DAS28 varied among countries from 3.1 to 6.0
(table 2), and was associated significantly with GDP
(r = 20.78, 95% CI 20.56 to 20.90, r
2 = 61%); a stronger
association (r = 20.85, 95% CI 20.63 to 20.94, r
2 = 72%)
was seen when only 18 European countries were included (fig 1;
data from USA presented as a reference in the figure). Among
European countries, an increase of GDP per 1000J translates to
a decrease of DAS28 of 20.10 (95% CI 20.061 to 20.13).
DISCUSSION
These data from the QUEST–RA database indicate that the
burden of RA is substantially greater in ‘‘low GDP’’ than in
‘‘high GDP’’ countries, within and outside of Europe. These
results are consistent with data concerning other chronic
diseases and general health in different countries.
7–9 17 The
burden of chronic diseases, recognised as an important neglected
global health issue,
18 is greatest in low and middle income
countries.
19 Most chronic diseases occur at substantially higher
frequency in individuals of low socioeconomic status, particu-
larly before the age of 65 years.
1–6 Poor outcomes of RA
including mortality are associated with low socioeconomic
status.
52 0
Associations of low socioeconomic status and poor health,
within and between countries, are regarded in most medical
literature as based primarily on limited access to medical care
and problems in the structure of clinical care,
21–23 reflecting a
‘‘biomedical model’’, the dominant paradigm of 20th century
medicine.
23 24 However, in the present study, all patients had
access to a rheumatologist, and 88–100% of patients had taken
DMARD, including 69–98% who had taken methotrexate.
Treatment-related variables were quite similar between ‘‘high
GDP’’ and ‘‘low GDP’’ countries, including 97% of patients who
had used DMARD, a delay of 9 months to the start of DMARD
after first symptoms, the number of DMARD ever taken (2.8
and 2.5); 86% and 84% had ever used methotrexate and the use
of methotrexate covered similarly 32% and 30% of disease
Table 3 RA measures in the QUEST–RA study in Europe and other countries, in descending order of GDP
Country
GDP 2005
per capita
(US$1000)
DAS28
(0–9.1),
mean
SJC
(0–28),
median
TJC
(0–28),
median
Physician
global
(0–10),
median
HAQ
physical
function
(0–3),
median
Pain
VAS
(0–10),
median
Patient
global
VAS
(0–10),
median
PS-HAQ
(0–3),
mean
ESR,
median
RF-
positive,
%
Erosive
disease,
%
Europe
Ireland 48.7 4.1 3 4 1.6 0.75 3.4 2.9 0.61 18 80 60
Denmark 47.9 3.4 1 2 1.3 0.63 2.6 2.8 0.53 14 73 64
Sweden 39.6 3.8 2 2 1.4 0.88 3.3 3.3 0.56 19 82 60
The Netherlands 38.9 3.1 1 0 0.7 0.75 2.5 2.7 0.54 15 69 44
Finland 37.3 3.3 1 1 0.9 0.63 2.8 2.8 0.46 13 75 56
UK 37.3 4.0 1 4 1.8 0.88 4.1 3.6 0.69 19 81 69
France 35.0 3.7 1 2 2.5 0.88 3.9 3.6 0.90 16 75 76
Germany 33.9 4.4 3 4 3.0 0.75 5.0 4.9 0.81 20 61 78
Italy 30.5 4.5 2 4 3.0 1.00 4.9 5.0 0.97 28 71 38
Spain 26.1 3.5 1 1 1.2 0.88 3.1 3.6 0.88 17 73 60
Greece 25.6 3.4 0 1 1.1 0.25 2.3 2.0 0.77 23 52 71
Hungary 10.9 5.1 5 7 3.3 1.38 5.2 5.1 1.08 26 93 93
Estonia 10.3 4.7 4 6 3.0 1.13 4.3 4.8 0.95 24 68 86
Poland 8.0 5.3 6 9 4.3 1.38 5.0 4.8 0.97 31 70 62
Lithuania 7.5 5.5 3 12 4.1 1.38 5.2 5.3 1.01 29 78 79
Latvia 7.0 5.2 4 8 4.9 1.38 5.1 5.7 0.93 26 85 97
Serbia 3.5 5.9 6 18 4.6 1.63 5.1 5.3 1.38 28 71 80
Kosovo 3.5 6.0 6 16 4.7 1.63 5.1 5.0 1.47 45 81 99
Non-Europe
USA 41.9 3.3 2 1 1.9 0.63 3.2 2.6 0.47 14 71 36
Canada 35.2 4.1 2 4 1.8 1.00 4.6 4.0 0.69 21 83 45
UAE 32.4 4.3 3 3 2.6 0.63 3.7 2.8 0.69 24 75 47
Russia 5.3 5.0 5 6 3.4 1.13 3.5 4.5 1.21 24 75 60
Turkey 5.0 4.2 0 2.5 2.0 0.88 4.2 4.6 0.94 30 68 56
Brazil 4.8 4.2 3 2 1.5 0.63 3.2 3.5 0.71 28 80 63
Argentina 4.7 5.3 9 10.5 4.7 1.00 5.0 4.7 1.13 30 90 68
Total 4.2 2 4 2.4 0.88 4.1 4.2 0.82 22 74 63
DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate; GDP, gross domestic product; HAQ, health assessment questionnaire; Physician global, physician
global estimate of status; PS-HAQ, psychological HAQ; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; UAE, United Arab Emirates;
VAS, visual analogue scale.
Extended report
Ann Rheum Dis 2009;68:1666–1672. doi:10.1136/ard.2009.109983 1669duration in ‘‘high GDP’’ and ‘‘low GDP’’ countries. Disease
activity levels appeared much more associated with the wealth
of the country than current medications (table 5). The current
use of biological agents appeared to have a greater inverse
association with disease activity in ‘‘low GDP’’ than in ‘‘high
GDP’’ countries (table 5).
GDP explained 61% of the variation in DAS28 scores,
consistent with extensive observations of differences in health
status and mortality in different nations according to a nation’s
wealth.
7–9 Differences in DAS28 scores according to GDP are at
least twice as great as improvements in DAS28 achieved in any
clinical trial of the most powerful biological agents. The data
echo a suggestion made by Virchow in 1848 that ‘‘the
improvement of medicine would eventually prolong human
life, but improvement of social conditions could achieve this
result now more rapidly and more successfully.’’
25
Many psychological constructs, including stress, anxiety,
depression, limited social support, learned helplessness and lack
of optimism, are prognostic of higher mortality rates in
individuals.
23 26–28 These reports suggest that associations of low
Table 4 GDP and treatment-related variables in the QUEST–RA study in Europe and other countries, in descending order of GDP
Country
GDP 2005
per capita
US$1000
Patients
taking
DMARD
ever, %
Delay to start
DMARD,
months,
median
No of
DMARD
ever taken
Methotrexate
ever, % of
patients
Prednisone
ever, % of
patients
Biologicals
ever, % of
patients
Any DMARD,
% of disease
duration
Methotrexate,
% of disease
duration
Biologicals,
%o f
disease
duration
Europe
Ireland 48.7 98.0 10.0 2.4 93 71 42 55.7 28.9 6.6
Denmark 47.9 99.0 10.0 2.8 86 44 23 65.6 25.5 2.9
Sweden 39.6 94.0 12.0 2.8 84 69 33 73.7 31.1 7.2
The Netherlands 38.9 99.0 5.0 2.3 92 30 23 87.6 45.0 4.4
Finland 37.3 100.0 7.0 4.0 86 74 17 109.6 25.7 2.2
UK 37.3 95.0 12.0 2.4 83 54 20 51.3 24.6 1.9
France 35.0 99.0 8.0 3.7 87 83 53 77.0 31.0 8.9
Germany 33.9 92.0 15.0 2.7 80 54 29 66.5 28.8 6.3
Italy 30.5 96.0 9.0 2.4 81 72 27 66.9 28.9 2.9
Spain 26.1 98.0 13.0 2.8 87 68 27 67.4 30.9 4.4
Greece 25.6 100.0 7.0 2.9 94 94 54 104.2 50.8 14.6
Hungary 10.9 96.0 12.0 2.6 85 58 16 54.3 20.1 0.7
Estonia 10.3 98.0 12.0 2.8 83 76 1 67.4 23.8 0.3
Poland 8.0 99.0 4.0 3.0 89 80 10 64.0 26.3 0.9
Lithuania 7.5 96.0 13.0 2.3 84 97 11 45.3 21.2 1.7
Latvia 7.0 98.0 24.0 2.2 92 79 23 52.9 28.0 1.6
Serbia 3.5 96.0 11.0 2.0 69 88 2 64.6 25.2 0.3
Kosovo 3.5 100.0 3.0 2.0 82 95 1 82.4 36.8 0.2
Non-Europe
USA 41.9 98 9.0 2.1 85 77 33 83.8 39.5 8.5
Canada 35.2 95 11.0 3.0 76 62 28 77.6 22.1 5.0
UAE 32.4 88 11.0 1.8 73 56 10 70.2 31.3 1.9
Russia 5.3 88 10.0 1.8 73 41 18 64.0 28.6 9.7
Turkey 5 99 12.0 2.4 89 75 7 75.3 33.4 0.7
Brazil 4.8 100 8.0 3.0 98 81 27 115.7 57.6 3.7
Argentina 4.7 88 13.0 1.5 68 83 3 46.3 24.5 0.5
Total 97 9 2.7 85 71 23 71.6 30.8 3.9
DMARD, disease-modifying antirheumatic drug; GDP, gross domestic product; UAE, United Arab Emirates.
Table 5 Disease activity in ‘‘high GDP’’ and ‘‘low GDP’’ countries, according to current medications
‘‘High GDP’’ countries ‘‘Low GDP’’ countries
p Value{ DAS28, mean DAS28, mean
Methotrexate
Taking methotrexate now 3.6 5.1 ,0.001
No methotrexate now 3.8 5.2 ,0.001
p Value* 0.003 0.028
Prednisone
Taking prednisone now 3.9 5.3 ,0.001
No prednisone now 3.5 4.8 ,0.001
p Value* 0.001 0.001
Biologicals
Taking biologicals now 3.7 4.4 ,0.001
No biologicals now 3.7 5.2 ,0.001
p Value* 0.63 ,0.001
*Comparison within ‘‘high GDP’’/‘‘low GDP’’ countries.
{Comparison between ‘‘high GDP’’/‘‘low GDP’’ countries.
DAS28, disease activity score in 28 joints; GDP, gross domestic product.
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explained as much or ever better by psychosocial and behavioural
variables as by ‘‘medical’’ variables, according to a ‘‘biopsychoso-
cial model’’ to complement a biomedical model.
23 24 27 28 In the
presentstudy,psychologicaldistressappearedsignificantlygreater
in ‘‘low GDP’’ than in ‘‘high GDP’’ countries.
Several limitations are seen in this study. First, cross-sectional
QUEST–RA data cannot address definitively whether the biology
of RA is more severe in less wealthy versus wealthy countries.
GDP may serve as a surrogate marker for many variables, some
related and others unrelated directly to medical care.
Second, a limited number of patients were included per
country. Nonetheless, results were quite similar among clinics
within each country.
10 Furthermore, it is not possible to obtain
optimal clinical information on large numbers of patients, with
accurate physical examination and physician-recorded diagnosis
for diseases such as RA, using only surveys. RA is not diagnosed
according to a single ‘‘gold standard’’ measure as seen for
hypertension or diabetes, but according to a set of measures,
requiring a knowledgeable clinician.
Third, it is possible that only RA patients with poor clinical
status visit clinics in countries with lower GDP, and patients
with better status in rich countries seek medical care. While this
possibility cannot be excluded, the study was designed to
incorporate a cross section of patients seen in various countries.
Clinical trials in patients with RA tend to be performed in
countries with lower GDP at this time, as most patients in
countries with higher GDP do not meet inclusion criteria,
29
indicating the likelihood of an accurate representation of the
present study.
These results illustrate the potential value of collaborative
databases, with identical database architecture, to provide an
opportunity to study associations between disease characteristics,
therapies and outcomes at many sites in many countries with
different economic levels. The QUEST–RA database may appear
somewhat complex, although the collected data were regarded as
consistentwithappropriategoodpatientcare.Theonlypayments
made to physicians were to cover the costs of materials and
mailing. Similar efforts could be conducted at low cost for many
diseases and add useful information regarding clinical status,
prognosis and monitoring.
The status of patients with RA has been found to be
significantly better in recent years than in previous decades.
30–32
However, almost all of the published data have been derived from
western European and north American nations. The data
presentedinthisreport,indicatingdisparitieswithothercountries,
present an important challenge. While it is possible that other
nations may ‘‘catch up’’ over the next decade to advances in the
wealthier nations at this time, disparities may continue to exist.
Public health efforts would appear potentially to be as important
as the introduction of new therapies to treat RA.
33
Further research is needed to understand better the structure
(demographic, macroeconomic), process (clinical and treatment
variables) and outcomes (mortality, functional and work
status), which may contribute to differences in quality of care
for patients with RA in different countries. Recognition of
major differences in outcomes can lead to more informed efforts
to improve the structure and process of care. The ultimate goal
of these efforts is to improve outcomes for patients with RA in
all countries.
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Figure 1 Association between gross domestic product per capita
(GDP) and disease activity score in 28 joints (DAS28) in 18 European
countries and the USA in the QUEST–RA study. The correlation of GDP
with DAS28 is r = 20.85 (95% CI 20.63 to 20.94); indicated with
colour. GDP is expressed as 1000J per capita. DAS28 ranges from 0 to
9.1 (low–high disease activity). The area of the disk is proportional to the
total national health expenditure of each country in 2004. De, Denmark;
Es, Estonia; Fi, Finland; Fr, France; Ge, Germany; Gr, Greece; Hu,
Hungary; Ir, Ireland; It, Italy; Ko, Kosovo; La, Latvia; Li, Lithuania; Ne, The
Netherlands; Po, Poland; Se, Serbia; Sp, Spain; Sw, Sweden.
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